NEO

14.17

3.20% 0.44

Dopo l'orario di chiusura: 14.09 -0.08 -0.56%

Neogenomics Inc (NEO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NEO Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$13.73

Aprire:

$13.69

Volume 24 ore:

7.13M

Relative Volume:

2.94

Capitalizzazione di mercato:

$1.85B

Reddito:

$745.97M

Utile/perdita netta:

$-99.21M

Rapporto P/E:

-18.33

EPS:

-0.7729

Flusso di cassa netto:

$-5.09M

1 W Prestazione:

+27.31%

1M Prestazione:

+52.86%

6M Prestazione:

+15.39%

1 anno Prestazione:

+97.91%

Intervallo 1D:

$13.60

$14.23

Intervallo di 1 settimana:

$10.96

$14.23

Portata 52W:

$4.72

$14.23

Neogenomics Inc Stock (NEO) Company Profile

Nome

Neogenomics Inc

Settore

Healthcare (1096)

Industria

Diagnostics & Research (48)

Telefono

(239) 768-0600

Indirizzo

9490 NEOGENOMICS WAY, FORT MYERS, FL

Dipendente

2,500

Cinguettio

@NeoGenomics

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, IDXX, A, NTRA

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NEO Neogenomics Inc	14.17	1.79B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	513.03	187.95B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	196.19	136.75B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	551.50	43.78B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	136.01	38.27B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.91	37.34B	2.50B	-226.32M	71.51M	-1.6412

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-30	Downgrade	BTIG Research	Buy → Neutral
2025-07-29	Downgrade	William Blair	Outperform → Mkt Perform
2025-05-15	Iniziato	Guggenheim	Neutral
2025-04-30	Downgrade	Leerink Partners	Outperform → Market Perform
2025-01-13	Downgrade	The Benchmark Company	Buy → Hold
2024-12-10	Iniziato	Jefferies	Buy
2024-05-01	Ripresa	Craig Hallum	Buy
2023-12-29	Reiterato	BTIG Research	Buy
2023-08-21	Aggiornamento	Stephens	Equal-Weight → Overweight
2023-05-16	Downgrade	Raymond James	Outperform → Mkt Perform
2023-05-09	Aggiornamento	BTIG Research	Neutral → Buy
2023-02-24	Aggiornamento	The Benchmark Company	Hold → Buy
2023-02-01	Aggiornamento	Needham	Hold → Buy
2022-08-26	Downgrade	The Benchmark Company	Buy → Hold
2022-08-22	Downgrade	Needham	Buy → Hold
2022-06-03	Iniziato	Piper Sandler	Overweight
2022-03-29	Downgrade	BofA Securities	Buy → Neutral
2022-03-29	Downgrade	Stephens	Overweight → Equal-Weight
2022-01-18	Ripresa	Stephens	Overweight
2021-12-16	Iniziato	Cowen	Outperform
2021-11-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-03	Iniziato	Goldman	Buy
2021-02-25	Ripresa	Needham	Buy
2021-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
2021-01-28	Iniziato	Truist	Buy
2020-12-11	Ripresa	BTIG Research	Buy
2020-10-28	Reiterato	Needham	Buy
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-08-28	Iniziato	Guggenheim	Buy
2020-07-29	Reiterato	Needham	Buy
2020-06-25	Iniziato	BofA/Merrill	Buy
2020-04-21	Ripresa	Stephens	Overweight
2020-03-02	Ripresa	Craig Hallum	Buy
2020-02-28	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Reiterato	Needham	Buy
2019-05-01	Reiterato	Needham	Buy
2019-03-29	Reiterato	Needham	Buy
2019-01-03	Iniziato	Needham	Buy
2018-10-24	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Iniziato	Leerink Partners	Outperform
2018-05-02	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Downgrade	BTIG Research	Buy → Neutral
2017-08-24	Iniziato	Gabelli & Co	Buy
2016-12-15	Iniziato	Cantor Fitzgerald	Overweight

Mostra tutto

Neogenomics Inc Borsa (NEO) Ultime notizie

12:17 PM

NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO) - TradingView

12:17 PM

12:16 PM

Enterprise value to EBITDA forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView

12:16 PM

08:08 AM

Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of NeoGenomics, Inc. – LSX:120159 - TradingView

Jun 26, 2026

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance

Jun 26, 2026

Jun 25, 2026

NEO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD - Investing.com UK

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD By Investing.com - Investing.com South Africa

Jun 25, 2026

NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants - Stock Titan

Jun 25, 2026

NeoGenomics (NEO) director Carolyn Starrett files initial Form 3 - Stock Titan

Jun 25, 2026

NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors - marketscreener.com

Jun 25, 2026

NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future - BriefGlance

Jun 25, 2026

NeoGenomics Appoints Carolyn Starrett to Board of Directors - citybiz

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors - Investing.com

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors By Investing.com - Investing.com Canada

Jun 25, 2026

NeoGenomics appoints Carolyn S. Starrett to its Board - TradingView

Jun 25, 2026

Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise - Stock Titan

Jun 25, 2026